G(
Therapeutic Areas
TriSalus Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nelitolimod (SD-101) via PEDD™ PRVI + systemic checkpoint inhibitors | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 |
| Nelitolimod (SD-101) via PEDD™ + systemic checkpoint inhibitors | Hepatocellular Carcinoma (HCC) | Phase 1/2 |
Leadership Team at TriSalus Life Sciences
SC
Steven C. Katz
Chief Executive Officer
MT
Mary T. Szela
Executive Chair of the Board
B(
Boris (Bo) R. Shkolnik
Founder